The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on on Innovation in Pharmaceuticals: Transcription factors for AAV. Buy the report here.

Smarter leaders trust GlobalData

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Transcription factors for AAV is a key innovation area in pharmaceutical

Adeno-associated virus (AAV) vectors are widely used for gene therapy. AAV genomes are highly compact, with overlapping coding regions, alternate splicing schemes, and multiple transcription initiation codons. There are two main genes in the AAV genome, rep and cap, which encode nine different proteins. Transcription of the rep gene is initiated from the p5 or p19 promoters to, respectively, produce the large (Rep78 and Rep68) and small (Rep52 and Rep40) nonstructural Rep proteins. Transcription of the cap gene is initiated from a single promoter termed p40. AAV virus infects cells to release ssDNA, and the virus then converts that ssDNA into a double-stranded DNA (dsDNA) template for transcription. Transfection of plasmids for rAAV production can initiate transcription directly from the dsDNA of these plasmids.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 60+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of transcription factors for AAV.

Key players in transcription factors for AAV – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to transcription factors for AAV

Company Total patents (2021 - 2023) Premium intelligence on the world's largest companies
Encoded Therapeutics 77 Unlock Company Profile
Takeda Pharmaceutical 70 Unlock Company Profile
Sanofi 67 Unlock Company Profile
Genethon 67 Unlock Company Profile
Esteve Pharmaceuticals 67 Unlock Company Profile
BioMarin Pharmaceutical 56 Unlock Company Profile
Centre National de la Recherche Scientifique 46 Unlock Company Profile
Children's Hospital of Philadelphia 44 Unlock Company Profile
Applied Genetic Technologies 38 Unlock Company Profile
Astellas Pharma 36 Unlock Company Profile
Nationwide Children's Hospital 36 Unlock Company Profile
Biogen 33 Unlock Company Profile
Sangamo Therapeutics 32 Unlock Company Profile
St. Jude Children’s Research Hospital 29 Unlock Company Profile
Fondazione Telethon 27 Unlock Company Profile
UniQure 26 Unlock Company Profile
Eyeserv 26 Unlock Company Profile
Pfizer 25 Unlock Company Profile
Adverum Biotechnologies 23 Unlock Company Profile
Massachusetts Eye and Ear Infirmary 22 Unlock Company Profile
Bayer 21 Unlock Company Profile
RegenxBio 19 Unlock Company Profile
Genepod Therapeutics 18 Unlock Company Profile
United States Of America 16 Unlock Company Profile
Life Sciences Research Partners VZW 16 Unlock Company Profile
Syncona 15 Unlock Company Profile
Regeneron Pharmaceuticals 14 Unlock Company Profile
Daiichi Sankyo 14 Unlock Company Profile
Decibel Therapeutics 13 Unlock Company Profile
Rocket Pharmaceuticals 13 Unlock Company Profile
AVROBIO 12 Unlock Company Profile
CLS Therapeutics 12 Unlock Company Profile
American Gene Technologies International 12 Unlock Company Profile
Cellectis 12 Unlock Company Profile
Vivet Therapeutics 11 Unlock Company Profile
Ultragenyx Pharmaceutical 11 Unlock Company Profile
Benitec Biopharma 11 Unlock Company Profile
Ecole Polytechnique Federale de Lausanne 11 Unlock Company Profile
ToolGen 11 Unlock Company Profile
SparingVision 11 Unlock Company Profile
Generation Bio 10 Unlock Company Profile
Voyager Therapeutics 10 Unlock Company Profile
Akouos 10 Unlock Company Profile
International Centre for Genetic Engineering and Biotechnology 10 Unlock Company Profile
Nemours Foundation 9 Unlock Company Profile
NanoScope Technologies 9 Unlock Company Profile
Precision Biosciences 8 Unlock Company Profile
Children's Healthcare of Atlanta 8 Unlock Company Profile
Lonza Group 7 Unlock Company Profile
Locanabio 7 Unlock Company Profile

Source: GlobalData Patent Analytics

Encoded Therapeutics is the leading patent filer in transcription factors for AAV. Encoded Therapeutics develops gene therapies for the treatment of severe genetic disorders. The company’s drug ETX-101, comprising a recombinant adeno-associated virus (AAV9) vector, is under development for the treatment of Dravet syndrome. The company is headquartered in South San Francisco, California, US. Takeda Pharmaceutical and Sanofi are the other key patent filers in transcription factors for AAV.

In terms of application diversity, Coda Biotherapeutics is the top company, followed by NanoScope Technologies and CLS Therapeutics. By means of geographic reach, Esteve Pharmaceuticals holds the top position. Pfizer and Biogen stand in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.